Enanta Pharmaceuticals Recognizes the 1st International NASH Day
June 12 2018 - 7:30AM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, is
proud to support the 1st International NASH Day taking place today.
This is a ground-breaking event organized by the NASH Education
Program and its benefactors and supporters around the world.
International NASH Day is taking place in more than 25 cities
worldwide where patients and providers will participate in
workshops, conferences and free screenings, and where the general
public will be engaged in street campaigning efforts. Additionally,
the initiative will be presented online, through web TV programming
in 6 languages, and across global social networks.
NASH is expected to become the #1 cause of liver transplant by
2020 in the United States, and its prevalence is projected to
increase globally in association with obesity and type 2-diabetes.
Yet NASH operates in silence by not showing symptoms. As a result,
it remains poorly-known and under-diagnosed, and as such represents
a growing global public health issue in most countries worldwide.
1
“NASH is a deteriorating liver disease often associated with
obesity and Type 2 diabetes. We are proud to join the NASH
Education Program’s initiative to better educate physicians and
patients about risk factors for NASH, a disease that is still
little known in the general population,” stated Nathalie Adda,
M.D., Enanta Pharmaceuticals’ Senior Vice President and Chief
Medical Officer.
ABOUT NASHNASH, or non-alcoholic steatohepatitis, is a
metabolic disease characterized by the accumulation of fat in the
liver, along with inflammation and the degeneration of liver cells.
The disease is associated with long-term risk of progression into
diminished liver functionality, leading to non-alcoholic cirrhosis,
liver insufficiency and possibly even liver cancer. It also is
associated with an increased risk of cardiovascular diseases which
represent the leading cause of mortality for NASH patients. The
rise of NASH is connected to type 2 diabetes and obesity epidemics
that are growing globally.
About the NASH Education ProgramTMThe NASH
Education Program aims to bring resources and information to
patients, the general public and the medical community at large.
Most patients affected by NASH don’t know that they suffer from
this disease until they reach the late stages of the disease. NASH
is a “silent” affliction and while patients may experience fatigue
or loss of appetite, their symptoms can often be associated with
other conditions, making it very difficult for physicians and
clinicians to get a good handle on NASH screening. By disseminating
information to patients and physicians, The NASH Education Program
hopes to allow for earlier diagnosis and provide patients with a
chance to manage the disease by adopting drastic lifestyle changes
and following a strict diet. This is often a challenge for
patients, not only because those changes need to be sustained over
the long term in order to be effective, but also because it
requires a financial and time commitment.
About EnantaEnanta Pharmaceuticals has used its robust,
chemistry-driven approach and drug discovery capabilities to become
a leader in the discovery of small molecule drugs for the treatment
of viral infections and liver diseases. Two protease inhibitors,
glecaprevir and paritaprevir, discovered and developed through
Enanta’s collaboration with AbbVie, have now been approved in
jurisdictions around the world as part of AbbVie’s direct-acting
antiviral (DAA) regimens for the treatment of hepatitis C virus
(HCV) infection, including the regimens marketed as MAVYRET™ (U.S.)
and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir) and VIEKIRA PAK®
(paritaprevir/ritonavir/ombitasvir/dasabuvir) (U.S.) and VIEKIRAX®
(paritaprevir/ritonavir/ombitasvir) (ex-U.S.).
Royalties from the AbbVie collaboration are helping to fund
Enanta’s research and development efforts, which are currently
focused on the following disease targets: non-alcoholic
steatohepatitis (NASH), primary biliary cholangitis (PBC),
respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Please visit www.enanta.com for more information.
____________________________
1
https://www.international-nash-day.com/about-international-nash-day/about-the-1st-edition/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180612005139/en/
Enanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024